SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference Transcript
All right. Welcome, everybody, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by the team, Malcolm Kuno, Priyanka Grover, and LaRhea Hall. I want to kick off Monday morning with the SpringWorks, and speaking on behalf of the company, we have CEO, Saqib Islam. Saqib?
Thanks, Anupam. It's a pleasure to be here as always, and we appreciate you and the JPMorgan team hosting us.
Before we begin, I'll remind everyone that today's presentation includes some forward-looking statements. So at SpringWorks, we develop therapies that can meaningfully improve the lives of patients with severe rare diseases and cancer. With the recent FDA approval of Ogsiveo, we are proud to be executing on our commitment to patients and their families. Beyond Ogsiveo, we believe that we have best-in-class data with mirdametinib, our MEK inhibitor that could support a second product approval for patients
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
